United Therapeutics Corporation $UTHR Shares Sold by Ashton Thomas Private Wealth LLC

Ashton Thomas Private Wealth LLC cut its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 79.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,012 shares of the biotechnology company’s stock after selling 7,913 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in United Therapeutics were worth $843,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. increased its position in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares during the period. Vontobel Holding Ltd. grew its stake in United Therapeutics by 12.0% during the 2nd quarter. Vontobel Holding Ltd. now owns 1,487 shares of the biotechnology company’s stock worth $427,000 after purchasing an additional 159 shares in the last quarter. US Bancorp DE grew its stake in United Therapeutics by 16.6% during the 2nd quarter. US Bancorp DE now owns 2,299 shares of the biotechnology company’s stock worth $661,000 after purchasing an additional 328 shares in the last quarter. Blair William & Co. IL increased its holdings in United Therapeutics by 22.1% during the 2nd quarter. Blair William & Co. IL now owns 1,343 shares of the biotechnology company’s stock worth $386,000 after purchasing an additional 243 shares during the period. Finally, Callan Family Office LLC raised its position in United Therapeutics by 258.3% in the 2nd quarter. Callan Family Office LLC now owns 3,468 shares of the biotechnology company’s stock valued at $997,000 after purchasing an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $483.25, for a total value of $4,010,975.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $17,774,418.25. This represents a 18.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $470.95, for a total transaction of $10,596,375.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 542,214 shares of company stock valued at $260,031,533 in the last three months. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $485.36 on Friday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $519.99. The firm has a market capitalization of $20.90 billion, a P/E ratio of 18.39, a P/E/G ratio of 2.58 and a beta of 0.85. The company’s fifty day moving average price is $486.75 and its 200 day moving average price is $427.47.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on UTHR shares. UBS Group boosted their price objective on United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 29th. HC Wainwright lifted their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Finally, Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.